CALR and cancer: This process enhances DC antigen presentation capacity in part through the release from cancer cells of danger-associated molecular patterns (DAMP) molecules, including high mobility group box 1 (HMGB1), calreticulin (CRT), heat shock protein 70 (HSP70) and adenosine triphosphate (ATP), that ultimately activate CD8+ T-cell adaptive responses [8].